Vaxart

VXRTPhase 2

South San Francisco, United StatesFounded 2004vaxart.com

Vaxart's mission is to transform global health by developing oral pill vaccines that provide mucosal and systemic immunity, offering a potentially revolutionary advance in immunization technology. The company leverages a proprietary oral delivery platform and is led by an experienced team of industry veterans with deep expertise in vaccine development and commercialization. As a publicly traded entity, Vaxart is focused on advancing its clinical pipeline and establishing strategic partnerships to accelerate the development of its novel vaccine candidates.

Founded

2004

Focus

Vaccines

VXRT · Stock Price

USD 635.25+387.75 (+156.67%)

Historical price data

AI Company Overview

Technology Platform

Proprietary oral recombinant vaccine delivery platform designed to generate both mucosal and systemic immunity using a pill format, eliminating the need for needles and cold-chain storage.

Pipeline Snapshot

40 drugs in pipeline

Drug	Indication	Stage
VXA-A1.1 + Fluzone®	Influenza	Phase 2
VXA-CoV2-1.1-S	COVID-19	Phase 2
BTA798 + Placebo	Rhinovirus	Phase 2
VXA-CoV2-3.1 + COMIRNATY® + VXA-CoV2-3.3	SARS-CoV2	Phase 2
AP611074 5% gel + AP611074 matching placebo	Condyloma	Phase 2

Funding History

Total raised: $185M

PIPE$100MArmistice CapitalJul 15, 2020

IPO$40MUndisclosedJun 28, 2018

Series B$30MUndisclosedJun 15, 2011

Series A$15MUndisclosedJun 15, 2007

Opportunities

The oral vaccine platform presents a massive opportunity to disrupt the traditional vaccine market by improving accessibility, compliance, and distribution logistics.

Success could lead to a broad portfolio targeting seasonal flu, pandemic threats, and other viral diseases with high unmet need for easier administration.

Risk Factors

Key risks include clinical trial failures inherent to drug development, the challenge of demonstrating efficacy comparable to injectable vaccines, regulatory hurdles for a novel delivery method, and the ongoing need for significant capital to fund operations as a pre-revenue company.

Competitive Landscape

Vaxart competes with large vaccine manufacturers (Pfizer, Moderna, GSK) and other biotechs exploring alternative delivery methods. Its primary differentiation is the oral pill format aimed at inducing mucosal immunity, a unique approach that, if proven effective, could carve out a significant niche in the market.